VYD2311

DRUG3 trials

Sponsors

Invivyd, Inc.

Conditions

COVID 19 VaccineCOVID LongCOVID-19COVID-19 (SARS-CoV-2 Infection)Long COVID

Phase 1

A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

Active, not recruitingNCT06523153

Invivyd, Inc.COVID-19

Start: 2024-08-28End: 2025-05-31Target: 40Updated: 2024-11-19

Phase 2

Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome

Not yet recruitingNCT07899346

Invivyd, Inc.COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine, COVID Long +1

Start: 2026-10-01End: 2027-06-01Target: 130Updated: 2026-10-27

Phase 3

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

CompletedNCT07655180

Invivyd, Inc.COVID-19

Start: 2026-06-08End: 2026-08-15Updated: 2026-10-14